Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening

Wei Zhu, Miao Xu, Catherine Z. Chen, Hui Guo, Min Shen, Xin Hu, Paul Shinn, Carleen Klumpp-Thomas, Samuel G. Michael, Wei Zheng*

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA

Supplementary Information

Table of Contents

Figure S-1. Triage strategy used to narrow down the starting 10,755 small molecules from the primary HTS campaign which led to the identification of 23 compounds having IC_{50}s < 30 µM, maximal inhibition > 60% against SARS-CoV-2 $3CL^{pro}$.

Figure S-2. Standard curve generated by diluting SGFRKME-Edans (fluorescent fragment in assay byproducts) in 20 µM substrate solution. The relative fluorescent unit (RFU) is linearly proportional to the amount of SGFRKME-Edans.

Figure S-3. Concentration-response curves of identified compounds by 3CL^{pro} assay. These compounds showed relatively negligible quenching effect relative to enzyme inhibitory activity.

Figure S-4. Concentration-response curves of compounds showed apparent quenching effect in counter screen.